Addyi, the First “Female Viagra,” Rises Again

2
169

From The Hastings Center Report: “Addyi, a drug that made a splash when it was approved in the summer of 2015 as the first ‘female Viagra,’ is back. Its rise, fall, and rise again is an example of shrewd pharmaceutical marketing and the potential dangers it can pose to patients.”

Article →

Support MIA

MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.

$
Select Payment Method
Personal Info

Credit Card Info
This is a secure SSL encrypted payment.

Billing Details

Donation Total: $20 One Time

2 COMMENTS

  1. Addyi is a SSRI which did not get FDA approval. In reviewing the data originally submitted for antidepressant approval, the drug was noted to have the typical adverse effects on sexual functioning that the other SSRIs show. When data was resubmitted for the female Viagra, there were no adverse effects on sexual functioning. One would expect that a substantial number of women prescribed this drug will show sexual dysfunction and other typical adverse SSRI effects.